DIA会员及用户请点击登录

登录

忘记用户 ID? or 忘记密码?

Not a Member?

创建账户并加入。

Online

2025 年 05 月 08 日 12:00 下午 - 2025 年 05 月 08 日 1:00 下午

(US Eastern Standard Time)

Rethinking Evidence: Leveraging Real-World Data to Accelerate Drug Development hosted by OM1

Join us to see how RWD, AI, and automation are reshaping observational studies—delivering faster insights, less burden, and regulatory-ready evidence.

Presenters

Nancy A Dreyer, PHD, MPH, FISPE

Nancy A Dreyer, PHD, MPH, FISPE

Founder, Dreyer Strategies LLC, United States

Nancy Dreyer served as Chief Scientific Officer at IQVIA Real World Solutions, Global Chief of Scientific Affairs at Outcome Sciences Inc and Quintiles, and CEO of Epidemiology Resources Inc. prior to switching to consultancy. She maintains active practice in the biopharmaceutical industry. Her primary research interest is to advance use of RWE including patient-generated health data, electronic medical records, medical and pharmacy claims, data linkage and data integration for studies of safety, effectiveness and natural history. She is a Fellow of ISPE, a Science and Policy Advisor and Fellow of DIA, Adjunct Professor of Epidemiology at the Univ of North Carolina at Chapel Hill and serves on ISPOR's RWE Leadership Team.

Eric  Schrock

Eric Schrock

Chief Technology Officer, OM1, United States

Eric Schrock is Chief Technology Officer and Head of Evidence Generation Solutions at OM1, where he leads a diverse technology team spanning product engineering, data engineering, product management, information security, and IT. He is responsible for shaping and driving OM1's digital strategy and overseeing product development in areas such as data analytics, patient and site experience, and AI-powered personalized medicine. Before joining OM1, Eric was the CTO at Jvion, where he managed teams across product delivery, engineering, professional services, and customer success.

获得信息并保持参与

不要错失任何机会——请加入我们的邮件列表,了解DIA的观点和事件。